Amgen's Repatha meets mark in CVOT

Hypercholesterolemia treatment Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) met the primary endpoint of the Phase III FOURIER cardiovascular outcomes trial by significantly reducing the risk of major cardiovascular events vs. placebo.

The composite primary endpoint measured time to cardiovascular death, myocardial infarction (MI), stroke, hospitalization for unstable angina or coronary revascularization. The PCSK9 inhibitor also met on at least one of FOURIER's secondary endpoints -- a reduction in the risk of cardiovascular death, MI or stroke...